Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + docetaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Nivolumab + docetaxel is a combination therapy comprising nivolumab, a monoclonal antibody targeting the PD-1 receptor, and docetaxel, a cytotoxic taxane chemotherapeutic agent. Nivolumab enhances the body's immune response against tumor cells by inhibiting the immune checkpoint PD-1, thereby restoring T-cell activity. Docetaxel works by stabilizing microtubules, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. This combination has shown improved progression-free survival and overall survival in patients with advanced non-small cell lung cancer (NSCLC) after failure of platinum-based chemotherapy[1][2]. It has also been investigated in metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors[3][4].
- Brand names
- nivolumab + docetaxel
- Other names
- nivolumab + docetaxel
02
Targets
MicrotubulePDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nivolumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + docetaxel.